462 related articles for article (PubMed ID: 25352393)
1. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Garnock-Jones KP
Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
3. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
4. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
5. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
6. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
7. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
DeSouza SA; Preston IR
Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
[TBL] [Abstract][Full Text] [Related]
8. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
[TBL] [Abstract][Full Text] [Related]
9. Riociguat: Clinical research and evolving role in therapy.
Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
[TBL] [Abstract][Full Text] [Related]
10. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Kim NH
Eur Respir Rev; 2010 Mar; 19(115):68-71. PubMed ID: 20956169
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
12. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
Kenny M; Clarke MM; Pogue KT
J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives.
Boutou AK; Pitsiou G
Expert Opin Pharmacother; 2020 Jul; 21(10):1145-1155. PubMed ID: 32089012
[TBL] [Abstract][Full Text] [Related]
14. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
[TBL] [Abstract][Full Text] [Related]
16. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
17. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
[TBL] [Abstract][Full Text] [Related]
18. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
19. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
[TBL] [Abstract][Full Text] [Related]
20. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.
Benza RL; Farber HW; Frost A; Grünig E; Hoeper MM; Busse D; Meier C; Nikkho S; Ghofrani HA
J Heart Lung Transplant; 2018 Jul; 37(7):836-843. PubMed ID: 29580746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]